Who are Azacitidine combined HHT's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azacitidine-combined-hht.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Azacitidine combined HHT — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Azacitidine combined HHT (Azacitidine combined HHT) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hypomethylating agent combined with protein synthesis inhibitor. Area: Oncology.

phase 3 Hypomethylating agent combined with protein synthesis inhibitor DNA methyltransferase (DNMT) and eukaryotic translation elongation factor 2 (eEF-2) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Azacitidine combined HHT (Azacitidine combined HHT) — Shandong Provincial Hospital. Azacitidine inhibits DNA methyltransferase to reactivate silenced tumor suppressor genes, while HHT (homoharringtonine) inhibits protein synthesis to induce apoptosis in leukemic cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Azacitidine combined HHT TARGET	Azacitidine combined HHT	Shandong Provincial Hospital	phase 3	Hypomethylating agent combined with protein synthesis inhibitor	DNA methyltransferase (DNMT) and eukaryotic translation elongation factor 2 (eEF-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hypomethylating agent combined with protein synthesis inhibitor class)

Shandong Provincial Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Azacitidine combined HHT — Competitive Intelligence Brief. https://druglandscape.com/ci/azacitidine-combined-hht. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab